anlotinib + erlotinib

Anlotinib + erlotinib is a combination therapy that pairs two distinct targeted agents for the treatment of non-small cell lung cancer (NSCLC). This combination brings together anlotinib, a multi-target antiangiogenic tyrosine kinase inhibitor (TKI), with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. ## Efficacy and Clinical Development The combination has shown promising results in clinical trials. In a 3-armed exploratory study evaluating anlotinib combined with different standard strategies as first-line treatment for advanced NSCLC, the anlotinib + erlotinib arm demonstrated an impressive objective response rate (ORR) of 86.7% and a median progression-free survival (mPFS) of 21.6 months[1]. This represents a potentially significant improvement compared to historical data from other VEGF/VEGFR inhibitor combinations with EGFR-TKIs. The dosing regimen typically involves anlotinib at 10mg once daily on days 1-14 of a 21-day cycle, combined with erlotinib at a dose of 150mg once daily[2]. This combination has been studied specifically in patients with EGFR mutations, showing efficacy in both EGFR-mutated and wild-type EGFR patients. ## Safety Profile In clinical trials, 73.3% of patients treated with the anlotinib + erlotinib combination experienced grade-3 or worse treatment-related adverse events (TRAEs)[1]. The most common adverse events included rash, oral mucositis, diarrhea, hypertension, proteinuria, and liver enzyme elevations (ALT and AST increases). One patient experienced grade-4 hypertension. Notably, 40% of patients required dosage adjustments due to adverse events, suggesting that determining the optimal dosing for this combination remains an area for further investigation[1]. ## Mechanism of Action This combination leverages complementary mechanisms: 1. Anlotinib targets multiple kinases involved in tumor angiogenesis and proliferation, including VEGFR, PDGFR, FGFR, and c-Kit 2. Erlotinib specifically inhibits EGFR tyrosine kinase activity, blocking cell signaling pathways that promote cancer cell growth and survival The rationale behind this combination is that simultaneously targeting both angiogenesis (with anlotinib) and EGFR signaling (with erlotinib) may provide enhanced anti-tumor activity compared to either agent alone, potentially overcoming or delaying resistance mechanisms. The combination has been studied primarily in the context of advanced NSCLC, particularly in patients with EGFR mutations, as both first-line therapy and in patients who have progressed on previous EGFR-TKI treatment[1][5].